Exoskeleton-Assisted Mobility in Aging and in Parkinson's Disease
Exoskeleton-Assisted Mobility in Aging and in Parkinson's Disease: A Mixed-Methods Study of Effectiveness and Acceptability
This study will evaluate whether a wearable robotic exoskeleton can improve mobility, balance, and walking in healthy older adults and in individuals living with Parkinson's disease, populations at high risk of falls and mobility limitations. Participants will attend two laboratory sessions. The first session includes clinical assessments, fitting and familiarization with the exoskeleton, and interviews to explore user perceptions. The second session involves performing functional mobility tasks (e.g., walking, standing, turning) with and without the exoskeleton and under different assistance levels, while movement is measured using wearable sensors.
The study will assess the immediate effects of the exoskeleton on mobility, compare assistance levels, identify which participants benefit most, and explore user experience and acceptability. Findings will help inform the development and implementation of assistive technologies to support mobility in healthy aging and in individuals with Parkinson's disease.
調査の概要
詳細な説明
Age-related declines in balance and walking ability increase the risk of falls, a leading cause of injury, loss of independence, and reduced quality of life among older adults. These challenges are even more pronounced in people living with Parkinson's disease, a neurological condition that affects movement and further impairs gait and postural stability. Although medications and rehabilitation can provide some benefit, mobility limitations often persist. Wearable exoskeletons have emerged as a promising approach to improve walking and reduce effort; however, their effectiveness and acceptability in individuals with Parkinson's disease remain insufficiently understood, particularly in real-world functional tasks.
The primary objective of this study is to determine the immediate effect of using a mobility-assistive exoskeleton on objective measures of balance and gait in healthy older adults and in individuals living with Parkinson's disease, and to explore user experience and acceptability.
The specific objectives are to: 1) Identify participant profiles (e.g., sex, age, severity of balance and gait impairments, severity of Parkinson's disease) that benefit the most from exoskeleton use, 2) Compare the effects of different levels of exoskeleton assistance on objective mobility measures relative to each participant's preferred assistance level, in order to determine whether this preferred level corresponds to the most effective level of assistance, 3) Determine whether the use of the exoskeleton improves balance and gait parameters, 4) Describe the perceptions of healthy older adults and in individuals with Parkinson's disease regarding the use of an exoskeleton in daily life, with particular attention to their interest, perceived benefits, barriers, and concerns related to its use, and 5) Explore how perceptions of exoskeleton use in daily life may change following a supervised exoskeleton use experience.
The study will be conducted in a laboratory setting and will take place over two separate sessions spaced at least two days and no more than four days apart. The first session will involve fitting and familiarizing participants with the exoskeleton, as well as conducting baseline clinical assessments (general health, mobility, balance, physical activity level, fatigue, mood, and cognitive function). During this session, participants will also undergo two semi-structured interviews, one before and one after using the exoskeleton, to share their perceptions, expectations, and concerns about using an exoskeleton.
During the second session, participants will perform a series of functional mobility tests both with and without the exoskeleton. When testing mobility with the exoskeleton, levels of assistance will manipulated to determine whether more or less support leads to better performance, and whether a participant's preferred level of assistance is also the most effective. Kinematics data will be collected using accelerometers to measure detailed aspects of walking, such as speed, step length, and variability.
For participants with Parkinson's disease, data collection will be conducted during the optimal effect of their usual dopaminergic medication, corresponding to the "ON" state.
The findings from this study will help determine whether exoskeletons are a useful and acceptable tool to support mobility in older adults and people with Parkinson's disease. In the long term, this research could contribute to the development of new strategies to reduce fall risk, improve independence, and enhance quality of life. It may also help guide healthcare professionals and technology developers in designing and implementing mobility aids that better meet the needs of these populations.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Alexandra Potvin-Desrochers, PhD
- 電話番号:335671 819-966-6200
- メール:alexandra.potvin-desrochers@ssss.gouv.qc.ca
研究連絡先のバックアップ
- 名前:Lucas Michaud, PhD
- 電話番号:338067 819-966-6200
- メール:07.labotechsoins@ssss.gouv.qc.ca
研究場所
-
-
Quebec
-
Gatineau、Quebec、カナダ、J9H 3Z1
- 募集
- TechCare Research Lab - CISSS de l'Outaouais
-
コンタクト:
- Alexandra Potvin-Desrochers, PhD
- 電話番号:335671 819-966-6200
- メール:alexandra.potvin-desrochers@ssss.gouv.qc.ca
-
コンタクト:
- Lucas Michaud, PhD
- 電話番号:338067 819-966-6200
- メール:07.labotechsoins@ssss.gouv.qc.ca
-
主任研究者:
- Alexandra Potvin-Desrochers, PhD
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Participants with Parkinson's disease
Inclusion Criteria:
- Ability to walk for at least 30 minutes with or without minimal aid
- Diagnosis of idiopathic Parkinson's disease
- Hoehn and Yahr stage 1 to 4
Exclusion Criteria:
- Height smaller than 152 cm
- Severe vascular conditions of the lower limbs that may limit mobility or pose a risk.
- Presence of any implantable or external life-sustaining medical device such as a pacemaker
- Severe osteoporosis or high risk of fractures
- Contra-indication to the required physical effort
- Severe cognitive impairment (MoCA < 21)
- Presence of neurological disorders, lower-limb injuries, or other conditions interfering with mobility, other than Parkinson's disease.
Healthy elderly participants without Parkinson's disease
Inclusion Criteria:
- Ability to walk for at least 30 minutes with or without minimal aid
- Age ≥ 65 years old
Exclusion Criteria:
- Height smaller than 152 cm
- Severe vascular conditions of the lower limbs that may limit mobility or pose a risk.
- Presence of any implantable or external life-sustaining medical device such as a pacemaker
- Severe osteoporosis or high risk of fractures
- Contra-indication to the required physical effort
- Severe cognitive impairment (MoCA < 21)
- Presence of neurological disorders, lower-limb injuries, or other conditions interfering with mobility
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Conditions
The effect of the exoskeleton on mobility will be evaluated under six different conditions: (1) without the exoskeleton (pre), (2) preferred assistance, (3) low assistance, (4) high assistance, (5) neutral assistance, and (6) without the exoskeleton (post).
The order of conditions 2 to 5 will be randomized.
All participants will undergo all six conditions.
|
The exoskeleton assistance in condition 2 will correspond to the preferred assistance level determined during the first session using an iterative approach.
For conditions 3 and 4, four exoskeleton parameters will be adjusted: eccentric load assistance, concentric load assistance, assistance during lower-limb flexion in the swing phase, and assistance during lower-limb extension in the swing phase.
The increased and decreased assistance conditions will correspond to an increase and a decrease of 3 Nm, respectively, for each of these parameters.
A minimum assistance of 1 Nm per parameter will be maintained when the baseline preferred assistance level is low.
During condition 5, the exoskeleton will be set to free mode, meaning that no assistance will be provided, but motor resistance will be eliminated.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Changes in Timed Up and Go (TUG) duration
時間枠:Through intervention completion, on average one hour
|
Participants will be required to stand up from a chair, walk 3 meters, turn around, return to the chair, and sit down.
The time will be measured between the starting signal ("go") and the moment the participant is seated again.
TUG is a reliable test to assess fall risk.
|
Through intervention completion, on average one hour
|
|
Changes in 10 meters walk test (10MWT) walking speed
時間枠:Through intervention completion, on average one hour
|
This test involves walking at a natural pace along a 10-meter segment, continuously for a duration of 1 minute.
The first and last meters of the segment are used to allow for the 180° turn and are not included in the analysis.
The choice of a continuous 1-minute protocol was made in accordance with current recommendations to ensure the validity and reliability of gait measurements using accelerometers.
|
Through intervention completion, on average one hour
|
|
Changes in 5 repetitions sit-to-stand test (5STS) duration
時間枠:Through intervention completion, on average one hour
|
The sit-to-stand test assesses the participant's ability to rise from a chair without using the arms.
The participant sits with feet flat on the floor and legs shoulder-width apart, then stands up while keeping the arms crossed over the chest.
The time required to complete five repetitions is recorded.
|
Through intervention completion, on average one hour
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Changes in gait variability
時間枠:Through intervention completion, on average one hour
|
The Mobilise-D algorithm will be used to quantify step length variability during the 1-minute 10MWT.
|
Through intervention completion, on average one hour
|
|
Exoskeleton acceptability (qualitative data, before exoskeleton use)
時間枠:Baseline
|
A descriptive qualitative thematic analysis will be conducted following Braun and Clarke approach on qualitative data obtained during the first semi-structured interview (before exoskeleton use).
A coding tree will be developed in which each unit of meaning will be assigned a label (i.e., a code).
These codes will then be grouped into categories from which the key themes will emerge.
This is a semi-inductive analytic process in which themes from the interview guide will serve as the basis for the initial coding, with additional codes added as they emerge from the interview content.
Categories and themes will be discussed within the research team until consensus is reached.
|
Baseline
|
|
Changes in exoskeleton acceptability (qualitative data, post exoskeleton use compared to pre)
時間枠:Immediately after the intervention
|
A descriptive qualitative thematic analysis will be conducted following Braun and Clarke approach on qualitative data obtained during the second semi-structured interview (after exoskeleton use).
A coding tree will be developed in which each unit of meaning will be assigned a label (i.e., a code).
These codes will then be grouped into categories from which the key themes will emerge.
This is a semi-inductive analytic process in which themes from the interview guide will serve as the basis for the initial coding, with additional codes added as they emerge from the interview content.
Categories and themes will be discussed within the research team until consensus is reached, and will be compared to those obtained following the first semi-structured interview (pre exoskeleton use).
|
Immediately after the intervention
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 2026-266
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IPD 共有時間枠
IPD 共有アクセス基準
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Exoskeletonの臨床試験
-
TOPMEDNatural Sciences and Engineering Research Council, Canada; Institut de Recherche Robert-Sauvé...募集
-
FIDMAG Germanes HospitalàriesHospital Aita Menni; ASPACE Gipuzkoa完了
-
Wearable Robotics srl.Azienda Ospedaliero, Universitaria Pisana; University Hospital, Geneva; Ecole Polytechnique Fédérale...終了しました
-
Centre Hospitalier Universitaire de Nīmes完了
-
Wearable Robotics srl.Fondazione Don Carlo Gnocchi Onlus募集